Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Molecular imaging of prostate cancer.

Fox JJ, Schöder H, Larson SM.

Curr Opin Urol. 2012 Jul;22(4):320-7. doi: 10.1097/MOU.0b013e32835483d5. Review.

2.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
3.

Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.

Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.

J Nucl Med. 2015 Dec;56(12):1862-8. doi: 10.2967/jnumed.115.162610.

4.

C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.

Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA.

Clin Nucl Med. 2011 Mar;36(3):192-8. doi: 10.1097/RLU.0b013e318208f140.

5.

The roles of PET and PET/CT in the diagnosis and management of prostate cancer.

Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K.

Oncology. 2007;72(3-4):226-33. doi: 10.1159/000112946. Review.

PMID:
18176088
6.

Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.

Tiwari BP, Jangra S, Nair N, Tongaonkar HB, Basu S.

Indian J Cancer. 2010 Oct-Dec;47(4):385-90. doi: 10.4103/0019-509X.73572.

7.

[State of the art in nuclear imaging for the diagnosis of bone metastases].

Ouvrier MJ, Vignot S, Thariat J.

Bull Cancer. 2013 Nov;100(11):1115-24. doi: 10.1684/bdc.2013.1847. Review. French.

PMID:
24153039
8.

Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H.

AJR Am J Roentgenol. 2012 Nov;199(5):1114-20. doi: 10.2214/AJR.11.8351.

PMID:
23096187
9.

18F-FDG PET/CT superscan in prostate cancer.

Bailly M, Besse H, Kerdraon R, Metrard G, Gauvain S.

Clin Nucl Med. 2014 Oct;39(10):912-4. doi: 10.1097/RLU.0000000000000376.

PMID:
24566401
10.

[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.

Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S.

BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x.

11.

¹⁸F-NaF PET/CT and ¹¹C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.

Koo PJ, David Crawford E.

Oncology (Williston Park). 2014 Dec;28(12):1057-62, 1064-5. Review.

PMID:
25738199
12.

The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.

Tabrizipour AI, Dunne M.

Clin Nucl Med. 2015 May;40(5):e285-6. doi: 10.1097/RLU.0000000000000681.

PMID:
25608148
13.

Positron emission tomography and bone metastases.

Fogelman I, Cook G, Israel O, Van der Wall H.

Semin Nucl Med. 2005 Apr;35(2):135-42. Review.

PMID:
15765376
14.
15.

The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer.

Yi C, Yu D, Shi X, Zhang X, Luo G, He Q, Zhang X.

Nucl Med Commun. 2016 Mar;37(3):239-46. doi: 10.1097/MNM.0000000000000444.

16.
17.

Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers: An Overview.

Azad GK, Taylor B, Rubello D, Colletti PM, Goh V, Cook GJ.

Clin Nucl Med. 2016 Jan;41(1):e44-50. Review.

PMID:
26402127
18.

Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.

Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR.

Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):607-11.

PMID:
12589476
19.

[PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].

García JR, Soler M, Blanch MA, Ramírez I, Riera E, Lozano P, Pérez X, Delgado E, Carrio I, Lomeña F.

Rev Esp Med Nucl. 2009 May-Jun;28(3):95-100. Spanish.

20.

Nuclear medicine studies of the prostate, testes, and bladder.

Jana S, Blaufox MD.

Semin Nucl Med. 2006 Jan;36(1):51-72. Review.

PMID:
16356796

Supplemental Content

Support Center